debt_leverage_profile
Minimal debt; cash-rich balance sheet (~$600M cash). 20% rate rise immaterial to operations; slight drag on float yield offset.
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; no significant floating-rate debt. Higher rates modestly boost interest income on cash reserves.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Schrödinger is software/IP-based; no material physical supply chain chokepoints. GPU compute (NVIDIA) and cloud capacity are key dependencies.
Inferred
Agent_Inference
international_expansion_readiness
Top international markets: EU, Japan, China. EUR and JPY devaluation risk moderate; China revenue small but RMB controls add repatriation risk.
Inferred
Agent_Inference
geographic_footprint
Operations in US, EU, Japan, China. ~30-35% revenue international. EUR depreciation most material; JPY weakness compresses yen-denominated contract values.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
AWS/GCP cloud infrastructure and NVIDIA GPU supply are non-substitutable on short notice; neither alone exceeds 30% of opex but combined are critical.
Inferred
Agent_Inference
business_model_type_primary
SaaS/platform software. Cloud termination in 30 days would severely disrupt delivery; migration feasible but 6-12 months minimum; customer SLAs at risk.
Inferred
Agent_Inference
business_model_type_secondary
Drug discovery collaboration model (milestone+royalty). Cloud disruption would halt computational workflows, endangering pharma partner deliverables and milestone payments.
Inferred
Agent_Inference
switching_cost_profile
High API coupling risk; Schrödinger's FEP+ and Maestro platform deeply embedded in customer workflows. Re-integration to competitor tools takes 12-24 months.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue is software licensing and R&D services, not investment contracts. No token or passive-return structure present.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure; handles proprietary drug candidate data for pharma clients. Data processing agreements and SCCs required; breach liability meaningful.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche computational chemistry market. No dominant market share trigger; competition from Rosetta, OpenEye, Atomwise limits concern.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~70-75% recurring (software subscriptions, multi-year pharma contracts); ~25-30% transactional (milestone payments, one-time collaboration fees).
Inferred
Agent_Inference
monetization_vector
Dual vector: SaaS seat/token licensing + success-based biopharmaceutical collaboration milestones and future royalties.
Inferred
Agent_Inference
pricing_architecture
Per-seat plus compute-usage pricing for software; milestone-gated payments for drug programs. Stress scenario: pharma budget cuts compress renewal ASPs 10-15%.
Inferred
Agent_Inference
pricing_power_rating
Moderate-high; switching costs and workflow integration support pricing power, but pharma procurement pressure and open-source alternatives (OpenMM) cap upside.
Inferred
Agent_Inference
target_gross_margin_bracket
55.7% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Minimal free-rider leakage; proprietary force fields and GPU-optimized code are paywalled. Academic licenses subsidized but not a meaningful revenue loss.
Inferred
Agent_Inference
headcount_cost_structure
Sublinear but not highly so; software revenue scales well, but drug discovery collaborations require PhD-level scientists, making that segment headcount-correlated.
Inferred
Agent_Inference
marginal_cost_of_growth
Software segment near-zero marginal cost; collaboration/drug-discovery segment has ~60-70% marginal cost due to scientist and compute requirements.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Schrödinger does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC efficiency improves for software but collaboration pipeline requires proportional BD and scientific staff; LTV/CAC likely 4-6x for SaaS segment.
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; value comes from proprietary data/models, not user density. Community-driven force field improvements add modest indirect network value.
Inferred
Agent_Inference
asset_efficiency_ratio
-14.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; large pharma clients have multi-year budgets, but biotech/startup segment (~30% of revenue) is highly sensitive to funding environment.
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biotech companies (Pfizer, Takeda, Bristol Myers Squibb); top 10 customers likely represent 50-60% of software+collaboration revenue.
Inferred
Agent_Inference
customer_segment_secondary
Academic and government research institutions; lower ASP, stable but not growth-driving segment, providing brand credibility and talent pipeline.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.6% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001490978
High
SEC-EDGAR
ticker
SDGR
High
SEC-EDGAR